MoonLake Immunotherapeutics Announces the Full Dataset from Its 24-week MIRA Clinical Trial, Establishing the Nanobody® Sonelokimab As a Highly Promising and Differentiated Therapeutic Solution for Hidradenitis Suppurativa koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising.
A European Academy of Dermatology and Venereology study explored the pathway from dermatologic consult to diagnosis to treatment and outcomes in the health care system.